Armed with results from a phase 2 trial, Boehringer Ingelheim has said it will take its obesity drug candidate survodutide into a phase 3 programme later this year. The glucagon/GLP-1 receptor dual ...

Abstract: This paper compares single-gate and dual-gate metasurfaces using indium tin oxide (ITO) near-zero permittivity for optical phase modulation in beam-steering applications. Published in: 2025 ...